OTC · Medical - Diagnostics & Research

Abingdon Health Plc (ABDXF) Stock

$0.13 +1.21% OTC: ABDXF Healthcare

Abingdon Health Plc is a global enterprise dedicated to the innovation, production, and worldwide distribution of diagnostic technologies. Their diverse product portfolio includes rapid self-diagnostic tools like the AbC-19 Rapid Test for detecting COVID-19 IgG antibodies and the 2019-nCoV Antigen Test for identifying SARS-CoV-2 antigens.

Valuation

MetricValue
Price$0.13
Market Cap$25.13M
P/E Ratio-11.61
P/B Ratio6.11
P/S Ratio1.97
EPS (TTM)$-0.01
52-Week High$0.21
52-Week Low$0.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-55.91%
ROA-30.73%
ROCE-62.02%
Gross Margin34.11%
Operating Margin-45.70%
Net Margin-33.88%
Debt/Equity0.15
Current Ratio1.91

Annual Financials (USD)

Metric20212022202320242025
Revenue$12.0M$3.0M$4.0M$6.0M$8.0M
Operating Profit$-6.0M$-12.0M$-4.0M$-1.0M$-4.0M
Net Profit$-7.0M$-21.0M$-3.0M$-1.0M$-3.0M
EPS$-0.07$-0.07$-0.01$0.00$-0.01
Op Margin-47.5%-427.0%-88.7%-22.4%-41.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$33.0M$13.0M$6.0M$5.0M$9.0M
Total Liabilities$12.0M$6.0M$3.0M$3.0M$4.0M
Cash$5.0M$2.0M$3.0M$1.0M$2.0M
Borrowings$1.0M$1.0M$1.0M$1.0M$1.0M

Latest News

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026 Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th GlobeNewswire · Jun 23, 2026 Abingdon Health plc to Present at the Life Sciences Investor Forum on June 25th GlobeNewswire · Jun 18, 2026 Small Cap Growth Virtual Investor Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 5, 2026 Abingdon Health plc to Present at the Small Cap Growth Virtual Investor Conference June 4th GlobeNewswire · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-8.0M$1.0M$-2.0M$-3.0M
Investing Cash Flow$-15.0M$-2.0M$0$0$-2.0M
Financing Cash Flow$0$0$0$0$-1.0M
Net Cash Flow$1.0M$-3.0M$1.0M$-2.0M$0
Free Cash Flow$-20.0M$-8.0M$1.0M$-2.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.53
EV / EBITDA-5.42
FCF Yield-13.71%
Quick Ratio1.73
Interest Coverage-56.08
Return 1Y89.40%
Return 3Y89.40%
Return 5Y—

Ownership

Insiders Held29.20%
Institutions Held30.76%
Institutions Float Held43.44%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CRPOFCeapro Inc. $0.17 -13.04% -3.74 $13.31M 0.00%
EIGRQEiger BioPharmaceuticals, Inc. $8.50 +6.25% -0.17 $12.59M 0.00%
MNNDFNurosene Health Inc. $0.33 -8.71% -0.82 $14.25M 0.00%
NOXOFNoxopharm Limited $0.05 +0.00% -5.00 $14.78M 0.00%
PXXLFPoxel S.A. $0.26 +0.00% -0.53 $16.14M 0.00%

About Abingdon Health Plc

Abingdon Health Plc is a global enterprise dedicated to the innovation, production, and worldwide distribution of diagnostic technologies. Their diverse product portfolio includes rapid self-diagnostic tools like the AbC-19 Rapid Test for detecting COVID-19 IgG antibodies and the 2019-nCoV Antigen Test for identifying SARS-CoV-2 antigens. They also offer a range of nucleic acid lateral flow immunoassays, including the PCRD and PCRD FLEX systems, which provide quick readouts following isothermal amplification. The 'Abingdon Simply Test' line further expands their selection of consumer-friendly self-tests. Beyond physical tests, Abingdon Health provides AppDx, an innovative, customizable image-capturing technology that essentially transforms any smartphone into a self-contained lateral flow reader. The company also extends its expertise through a variety of services, including contract manufacturing, bespoke nucleic acid lateral flow test customization, and comprehensive lateral flow development and production. Additionally, they offer strategic consultancy to businesses operating within the healthcare technology sector. Notably, Abingdon Health Plc maintains a significant collaboration and co-marketing agreement with Abcam plc. Founded in 2008, the company's operations are centrally managed from its headquarters in York, United Kingdom.

Abingdon Health Plc is headquartered in GB.

Abingdon Health Plc (ABDXF) stock trades at $0.13 with a market capitalization of $25.13M. The stock is valued at a price-to-earnings (P/E) ratio of -11.61, price-to-book of 6.11, price-to-sales of 1.97. Over the past 52 weeks the stock has ranged between $0.07 and $0.21, and currently trades 38.1% below its 52-week high.

On profitability, Abingdon Health Plc generates a return on equity (ROE) of -55.91%, return on capital employed of -62.02%, an operating margin of -45.70%, a net profit margin of -33.88%.

Official website: www.abingdonhealth.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides